TY - JOUR
T1 - Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages
T2 - update from ESGARS-ESCMID/ISARPAE Group
AU - Oliver, Antonio
AU - Rojo-Molinero, Estrella
AU - Arca-Suarez, Jorge
AU - Beşli, Yeşim
AU - Bogaerts, Pierre
AU - Cantón, Rafael
AU - Cimen, Cansu
AU - Croughs, Peter D.
AU - Denis, Olivier
AU - Giske, Christian G.
AU - Graells, Tíscar
AU - Daniel Huang, Te Din
AU - Iorga, Bogdan I.
AU - Karatuna, Onur
AU - Kocsis, Béla
AU - Kronenberg, Andreas
AU - López-Causapé, Carla
AU - Malhotra-Kumar, Surbhi
AU - Martínez, Luis Martínez
AU - Mazzariol, Annarita
AU - Meyer, Sylvain
AU - Naas, Thierry
AU - Notermans, Daan W.
AU - Oteo-Iglesias, Jesús
AU - Pedersen, Torunn
AU - Pirš, Mateja
AU - Poeta, Patricia
AU - Poirel, Laurent
AU - Pournaras, Spyros
AU - Sundsfjord, Arnfinn
AU - Szabó, Dora
AU - Tambić-Andrašević, Arjana
AU - Vatcheva-Dobrevska, Rossitza
AU - ESGARS-ISARPAE members
AU - Vitkauskienė, Astra
AU - Jeannot, Katy
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2024/4
Y1 - 2024/4
N2 - Scope: Pseudomonas aeruginosa, a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital-acquired and chronic infections associated with significant morbidity and mortality. This growing threat results from the extraordinary capacity of P. aeruginosa to develop antimicrobial resistance through chromosomal mutations, the increasing prevalence of transferable resistance determinants (such as the carbapenemases and the extended-spectrum β-lactamases), and the global expansion of epidemic lineages. The general objective of this initiative is to provide a comprehensive update of P. aeruginosa resistance mechanisms, especially for the extensively drug-resistant (XDR)/difficult-to-treat resistance (DTR) international high-risk epidemic lineages, and how the recently approved β-lactams and β-lactam/β-lactamase inhibitor combinations may affect resistance mechanisms and the definition of susceptibility profiles. Methods: To address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases launched the ‘Improving Surveillance of Antibiotic-Resistant Pseudomonas aeruginosa in Europe (ISARPAE)’ initiative in 2022, supported by the Joint programming initiative on antimicrobial resistance network call and included a panel of over 40 researchers from 18 European Countries. Thus, a ESGARS-ISARPAE position paper was designed and the final version agreed after four rounds of revision and discussion by all panel members. Questions addressed in the position paper: To provide an update on (a) the emerging resistance mechanisms to classical and novel anti-pseudomonal agents, with a particular focus on β-lactams, (b) the susceptibility profiles associated with the most relevant β-lactam resistance mechanisms, (c) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles, and (d) the globally expanding XDR/DTR high-risk lineages and their association with transferable resistance mechanisms. Implication: The evidence presented herein can be used for coordinated epidemiological surveillance and decision making at the European and global level.
AB - Scope: Pseudomonas aeruginosa, a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital-acquired and chronic infections associated with significant morbidity and mortality. This growing threat results from the extraordinary capacity of P. aeruginosa to develop antimicrobial resistance through chromosomal mutations, the increasing prevalence of transferable resistance determinants (such as the carbapenemases and the extended-spectrum β-lactamases), and the global expansion of epidemic lineages. The general objective of this initiative is to provide a comprehensive update of P. aeruginosa resistance mechanisms, especially for the extensively drug-resistant (XDR)/difficult-to-treat resistance (DTR) international high-risk epidemic lineages, and how the recently approved β-lactams and β-lactam/β-lactamase inhibitor combinations may affect resistance mechanisms and the definition of susceptibility profiles. Methods: To address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases launched the ‘Improving Surveillance of Antibiotic-Resistant Pseudomonas aeruginosa in Europe (ISARPAE)’ initiative in 2022, supported by the Joint programming initiative on antimicrobial resistance network call and included a panel of over 40 researchers from 18 European Countries. Thus, a ESGARS-ISARPAE position paper was designed and the final version agreed after four rounds of revision and discussion by all panel members. Questions addressed in the position paper: To provide an update on (a) the emerging resistance mechanisms to classical and novel anti-pseudomonal agents, with a particular focus on β-lactams, (b) the susceptibility profiles associated with the most relevant β-lactam resistance mechanisms, (c) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles, and (d) the globally expanding XDR/DTR high-risk lineages and their association with transferable resistance mechanisms. Implication: The evidence presented herein can be used for coordinated epidemiological surveillance and decision making at the European and global level.
UR - http://www.scopus.com/inward/record.url?scp=85182993342&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2023.12.026
DO - 10.1016/j.cmi.2023.12.026
M3 - Short survey
C2 - 38160753
AN - SCOPUS:85182993342
SN - 1198-743X
VL - 30
SP - 469
EP - 480
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 4
ER -
